Paul Howes brings over 30 years of commercial strategy, product development and management leadership experience, with a significant focus in the field of ophthalmology. He currently serves as a board member of ThromboGenics, and until the end of 2017 was the President and Chairman of its U.S. subsidiary, ThromboGenics, Inc.

 He previously served as a board member and CEO of Inotek Pharmaceuticals, a NASDAQ-listed ophthalmic drug development company. Prior to joining Inotek, Mr. Howes was President of the Americas Region for Bausch & Lomb with leadership responsibility for the United States, Canada, Latin America and South America across Bausch & Lomb’s Vision Care, Surgical and Pharmaceuticals business segments. Prior to joining Bausch & Lomb in 2003, Mr. Howes spent the previous 16 years in various senior management roles at Merck & Co. Inc. Prior to Merck, Mr. Howes spent 11 years at Price Waterhouse Canada. Mr. Howes is a graduate of Harvard College and earned his MBA from the Schulich School of Business at York University, Toronto, Canada. He also serves as a board member of Prevent Blindness, as a Trustee of BioNJ and as a board member of Kish Bancorp.

• 

  Executive Vice-President, Strategy & Business Development in Translatum Medicus Inc.

  AMD is the leading cause of irreversible blindness in the world and is growing globally.